摘要
目的探讨丹参酮ⅡA(TanⅡA)对糖尿病(DM)患者外周血中内皮祖细胞的影响及可能机制。方法将62例2型DM患者随机分为对照组和实验组,实验组在常规治疗基础上每天加用TanⅡA40mg,持续两周,测定治疗前后外周血中内皮祖细胞(EPCs)数量、EPCs表面CXCR4阳性率、基质细胞衍生因子-1(SDF-1)浓度。结果实验组治疗后较本组治疗前和对照组治疗后SDF-1、EPCs、CXCR4上升差异有统计学意义(P<0.05或P<0.01);EPCs与SDF-1有显著性正相关(r=0.223,P<0.05)。结论TanⅡA可能是通过提高外周血中SDF-1水平和上调CXCR4的表达,诱导EPCs从骨髓动员进入外周血中而改善2型DM患者内皮功能。
Objective To study the effect of tanshinone Ⅱ A （Tan ⅡA） on endothelial progenitor cells （EPCs） in patients with type 2 diabetes mellitus（T2DM）. Methods 62 cases patients with T2DM were randomly divided into treatment and control groups. Tan Ⅱ A 40mg/d were given for two weeks based on the routine treatment in patients of treatment group. The level of plasma Stromal cell - derived factor - 1 （ SDF - 1 ）, the number of EPCs and the positive rate of CXCR4 were determined before and after treatment. Results Increasing SDF - 1, EPCs and CXCR4 had significant difference in the treatment group pre and post treatment （P 〈 0.05 or P 〈 0.01 ） ; and those had significant difference between two groups （ P 〈 0.05 or P 〈 0.01 ）. There was a significant positive correlation between EPCs and SDF - 1 （ r = 0. 223, P 〈 0.05 ）. Conclusion Tanshinone Ⅱ A can improve vascular endothelial function in T2DM, which may be due to elevating the level of plasma SDF - 1 and increasing the expression of CXCR4 on EPCs, and inducing EPCs mobilization in bone marrow to peripheral blood.
出处
《海南医学》
CAS
2010年第1期39-41,共3页
Hainan Medical Journal
